IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Here’s Why

IPSEN (OTCMKTS:IPSEY) gapped up prior to trading on Thursday . The stock had previously closed at $34.35, but opened at $36.80. IPSEN shares last traded at $36.80, with a volume of 580 shares traded.

Analysts Set New Price Targets

IPSEY has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, BNP Paribas downgraded IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Trading Up 7.1%

The firm has a fifty day simple moving average of $35.95 and a 200 day simple moving average of $33.86.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).